ArriVent BioPharma, Inc.

Healthcare · Biotechnology · United States

Last price 15.95 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 786.46M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC...